Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. (2021)
Attributed to:
G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)01290-3
PubMed Identifier: 34090624
Publication URI: http://europepmc.org/abstract/MED/34090624
Type: Journal Article/Review
Volume: 397
Parent Publication: Lancet (London, England)
Issue: 10292
ISSN: 0140-6736